Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.
Amended and Restated Registration Rights Agreement dated March 29, 2017 giving the Investors demand and piggyback registration rights
Participation as purchasers in the February 2025 underwritten offering of common stock and pre-funded warrants (including BCLS II Investco, LP, Perceptive Life Sciences Master Fund, Ltd., RA Capital Healthcare Fund, LP, Adage Capital Partners, L.P., Invus Public Equities, L.P. and Vestal Point Capital, LP)
Participation as purchasers in the March 2026 private placement of common stock and pre-funded warrants (including Perceptive Life Sciences Master Fund, Ltd., Bain Capital Life Sciences Opportunities IV, L.P., RA Capital Healthcare Fund, LP, Invus Public Equities, L.P. and Vestal Point Capital, LP)
Participation as purchasers in the January 2024 private placement of common stock (including Perceptive Life Sciences Master Fund, Ltd., Adage Capital Partners, L.P., Deerfield Partners, L.P., Invus Public Equities, L.P., RA Capital Healthcare Fund, L.P. and BCLS II Equity Opportunities, LP)
Continued base salary for 18 months under the Ganot Transition Agreement following separation
Lump sum payment equal to 150% of target bonus for 2022 under the Ganot Transition Agreement
Employment with the company, with annual salary and bonus payments and equity awards (RSUs and options) granted in 2024, 2025 and 2026
Severance under the Morris Transition and Separation Agreement, paid ratably over 12 months from the separation date
Loading...
